Dabigatran Etexilate vs Dabigatran Etexilate Laboratorios Liconsa: Side-by-Side Comparison
Quick answer: Dabigatran Etexilate and Dabigatran Etexilate Laboratorios Liconsa are both direct thrombin inhibitor (doac) used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Dabigatran Etexilate | Dabigatran Etexilate Laboratorios Liconsa |
|---|---|---|
| Drug class | Direct thrombin inhibitor (DOAC) | Direct thrombin inhibitor (DOAC) |
| ATC code | B01AE07 | B01AE07 |
| Primary indications | Stroke prevention in atrial fibrillation, Venous thromboembolism treatment and prevention | Stroke prevention in atrial fibrillation, Venous thromboembolism treatment and prevention |
| Mechanism | Prodrug rapidly converted to dabigatran, which directly and reversibly inhibits thrombin (factor IIa) | Generic dabigatran etexilate; prodrug converted to dabigatran which directly inhibits thrombin (factor IIa) |
| Common dose | 150 mg twice daily | 150 mg twice daily |
| Detail page | Dabigatran Etexilate details → | Dabigatran Etexilate Laboratorios Liconsa details → |
How to choose between Dabigatran Etexilate and Dabigatran Etexilate Laboratorios Liconsa
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Direct thrombin inhibitor (DOAC) on iMedic · Dabigatran Etexilate full details · Dabigatran Etexilate Laboratorios Liconsa full details
Frequently asked questions
Is Dabigatran Etexilate better than Dabigatran Etexilate Laboratorios Liconsa?
Neither is universally 'better.' They are both direct thrombin inhibitor (doac) with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Dabigatran Etexilate to Dabigatran Etexilate Laboratorios Liconsa?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Dabigatran Etexilate and Dabigatran Etexilate Laboratorios Liconsa have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Dabigatran Etexilate and Dabigatran Etexilate Laboratorios Liconsa available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.